Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 4/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.91 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.91 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.91 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.91 |
| ▸ | LMNA | P02545 | 1/20 | 0.91 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.91 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.91 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.91 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.91 |
| ▸ | HTR3B | O95264 | 1/20 | 0.91 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.91 |
| ▸ | CHRNG | P07510 | 1/20 | 0.91 |
| ▸ | MAPT | P10636 | 1/20 | 0.91 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.91 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.91 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.91 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613093 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 | |
| SCHEMBL3612339 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 | |
| SCHEMBL5293891 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 | |
| SCHEMBL6802478 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 | |
| SCHEMBL6802481 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 | |
| SCHEMBL6802707 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 | |
| Bromide SCHEMBL7331542 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 | |
| SCHEMBL6802708 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 | |
| SCHEMBL6802483 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 | |
| (+/-)Nicotine SCHEMBL797620 | 0.95 | ALDH1A1 (1.00) | CHRNB2CHRNA7CHRNA4ALDH1A1CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113009046-A | GC-MS-MS detection and analysis method for synthesizing nicotine | 山东金城医药化工有限公司 | 2021-06-22 | — | — | CN | claimed |
| CN-107525865-B | Detection method for simulating generation of secondary alkaloid by nicotine degradation in actual environment | 国家烟草质量监督检验中心 | 2020-03-31 | — | — | CN | claimed |
| CN-107515263-A | Method that is a kind of while determining 11 kinds of secondary alkaloids in tobacco juice for electronic smoke | 国家烟草质量监督检验中心 | 2017-12-26 | — | — | CN | claimed |
| CN-107462649-A | Method that is a kind of while determining 12 kinds of alkaloids in electronics smoke sol | 国家烟草质量监督检验中心 | 2017-12-12 | — | — | CN | claimed |
| CN-107255687-A | It is a kind of at the same determine nicotine in 11 kinds of secondary alkaloid impurity contents method | 国家烟草质量监督检验中心 | 2017-10-17 | — | — | CN | claimed |
| US-20150203859-A1 | NUCLEIC ACID SEQUENCES ENCODING TRANSCRIPTION FACTORS REGULATING ALKALOID BIOSYNTHESIS AND THEIR USE IN MODIFYING PLANT METABOLISM | 22ND CENTURY LIMITED, LLC (US) | 2015-07-23 | — | — | US | claimed |
| EP-2549995-A2 | USE OF ANATABINE TO TREAT INFLAMMATION AND METHODS OF SYNTHESIZING ANATABINE | Rock Creek Pharmaceuticals, Inc. (US) | 2013-01-30 | — | — | EP | claimed |
| US-20110237627-A1 | METHODS OF SYNTHESIZING ANATABINE | Rock Creek Pharmaceuticals, Inc. (US) | 2011-09-29 | — | — | US | claimed |
| WO-2011119722-A2 | USE OF ANATABINE TO TREAT INFLAMMATION AND METHODS OF SYNTHESIZING ANATABINE | Rock Creek Pharmaceuticals, Inc. (US) | 2011-09-29 | — | — | WO | claimed |
| CN-100364990-C | Substituted 4-amino-1- (pyridylmethyl) piperidines and related compounds | THERAVANCE INC (US) | 2008-01-30 | — | — | CN | claimed |
| EP-1458252-B1 | TOBACCO AND/OR TOBACCO IN COMBINATION WITH TOBACCO SUBSTITUTE COMPOSITION FOR USE AS A SNUFF IN THE ORAL CAVITY | GALENICA AB (SE) | 2008-01-23 | — | — | EP | claimed |
| CN-1708494-A | Substituted 4-amino-1- (pyridylmethyl) piperidines and related compounds | THERAVANCE INC (US) | 2005-12-14 | — | — | CN | claimed |
| US-20050061339-A1 | Tobacco and/or tobacco substitute composition for use as a snuff in the oral cavity | GALENICA AB (SE) | 2005-03-24 | — | — | US | claimed |
| EP-1458252-A2 | TOBACCO AND/OR TOBACCO SUBSTITUTE COMPOSITION FOR USE AS A SNUFF IN THE ORAL CAVITY | Galenica AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2003053175-A2 | TOBACCO AND/OR TOBACCO SUBSTITUTE COMPOSITION FOR USE AS A SNUFF IN THE ORAL CAVITY | GALENICA AB (SE) | 2003-07-03 | — | — | WO | claimed |
| US-20250163443-A1 | METHODS FOR PRODUCING LOW-NICOTINE TOBACCO | UNIV NORTH CAROLINA STATE (US) | 2025-05-22 | — | — | US | disclosed |
| EP-3871674-B1 | USE OF ANATABINE FOR REDUCING BLOOD SERUM LEVELS OF C-REACTIVE PROTEIN IN AN INDIVIDUAL | PHILIP MORRIS PRODUCTS SA (CH) | 2024-12-25 | — | — | EP | disclosed |
| EP-0567251-A1 | Treatment of neurodegenerative diseases | R.J. REYNOLDS TOBACCO COMPANY (US) | 1993-10-27 | — | — | EP | disclosed |
| EP-0500658-A1 | A NICOTINE CONTAINING STIMULANT UNIT. | DAM ANDERS (DK) | 1992-09-02 | — | — | EP | disclosed |
| WO-1991006288-A1 | A NICOTINE CONTAINING STIMULANT UNIT | DAM ANDERS (DK) | 1991-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237627-A1 | METHODS OF SYNTHESIZING ANATABINE | ALKBH1, ALKBH2, NME2 | CHRNB2 1366/4885CHRNA7 2481/4885CHRNA4 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.